Trellus Health Announces Experienced Leaders to Drive Next Phase of Growth
Industry veterans from Teladoc Health, Talkspace, Harwood Capital and Polar Capital join executive team and board of directors
White Plains, May 3, 2021: Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its executive team and board of directors.
The company named Alex Kozersky as Chief Sales Officer, Bob Birdsong as Chief Marketing Officer and Carole Romasco as Vice President of Product Management. Jaime King was promoted to Vice President of Compliance, Operations, and Human Resources.
The Trellus Health Board of Directors also welcomed Christopher Mills of Harwood Capital and Daniel Mahony, PhD from Polar Capital as Non-Executive Directors.
Trellus Health’s proven resilience-driven methodology was validated on hundreds of patients with inflammatory bowel disease (IBD) at the Susan and Leonard Feinstein IBD Clinical Center at Mount Sinai, where Crohn’s disease was first identified by Dr. Burrill B. Crohn, MD in 1932.
Trellus Health Co-Founders, Marla Dubinsky, MD, and Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, have delivered their resilience-driven approach to hundreds of patients at the IBD Clinical Center for more than six years.
Alex Kozersky joins as Chief Sales Officer at Trellus Health. Based in New York, he previously worked as SVP of Health Plan Business Development at Talkspace, an online therapy platform accessed by over 1 million users.
Bob Birdsong, Chief Marketing Officer, brings over 26 years of marketing communications experience. He has formally served as the Chief Marketing Officer for Localist and the Human Capital Institute (HCI) in addition to serving as the VP of Marketing for Gartner and SMS Holdings.
In addition, Carole Romasco joins the senior team at Trellus Health as VP of Product Management. Prior to joining, she was Director of Product Management at Teladoc Health and VP of Product Development at Health Advocate.
Alongside the new joiners, the company promoted Jaime King, CNP, RHIT, CDIP to VP of Operations. Jaime has over 15 years of clinical administration and digital health experience in operational and leadership roles. Prior to Trellus Health, Jaime held leadership positions at iCoreConnect, ICDLogic, and several private healthcare practices.
Christopher Mills, CEO of Harwood Capital Management Limited joined as a Non-Executive Director. Alongside his role at Harwood Capital Management, he is CIO of North Atlantic Smaller Companies Investment Trust (NASCIT), which he has managed since 1982, and non-executive director a number of public companies. He also co-founded J O Hambro Capital Management in 1993 and acted as PM until its sale in 2011.
Daniel Mahony, PhD, also joined as Non-Executive Director. Daniel is the Co-Head of Healthcare at Polar Capital and has over 29 years of experience. Prior to his current role, he was head of the European healthcare research team at Morgan Stanley, covering European biotechnology, medical technology, and healthcare services sectors.
On this news, Trellus Health’s CEO Monique Fayad comments, “This incredibly high caliber management team expansion signifies an important milestone for Trellus and our growth. Our proprietary resilience-driven approach — deeply rooted and based on scientifically validated methodology — inspires hope and significantly improves outcomes for people suffering with chronic conditions. This leadership team will make our vision of creating a world where every person with a chronic condition has hope and thrives, a reality.”
About Trellus Health
Trellus Health is a leading pioneer in resilience-driven care for people with complex chronic conditions. Through its multidisciplinary connected care platform, TrellusElevateTM , Trellus coordinates expert whole-person care, including both clinical and behavioral health, to improve outcomes and to reduce healthcare costs for patients, employers, and the healthcare system.
The company was founded by Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, respectively. Trellus Health’s patent-pending GRITT-IBDTM resilience assessment and personalized treatment methodology was developed and validated at the Mount Sinai Health System to build resilience and wellness for improved outcomes at lower cost.
The resilience-driven connected care solution described is based on technology developed by Mount Sinai faculty and licensed to Trellus Health. Mount Sinai and Mount Sinai faculty members Marla Dubinsky, MD, and Laurie Keefer, PhD, have a financial interest in Trellus Health.
Bob Birdsong, Chief Marketing Officer
Tel (+1) 615-739-8461
UK Media and Investor Relations
via Walbrook PR
Tel +44 (0)20 7933 8780
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases.
The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island.
The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
Notes to editors
- Resilience-driven care incorporates positive psychology principles into all aspects of chronic disease management, with a focus on building acceptance, optimism, self-regulation, self-efficacy, and social support. Proven health benefits of resilience include increased longevity, cardiovascular, immune, and cognitive function, as well as physical well-being and reduced risk for depression and anxiety.
- Inflammatory bowel disease (IBD), a group of disorders that includes Crohn’s disease (first identified by Mount Sinai physician Dr. Burrill B. Crohn, MD, in 1932) and ulcerative colitis, imposes a substantial social and economic burden on patients, their employers, and the overall health system. IBD patients with a behavioral comorbidity — such as depression or anxiety — are at risk of costing the health system three to five times more than other patients due to the expense of unplanned emergency visits and hospital admissions.
- The company was founded by Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer, PhD:
- Dr. Dubinsky is Chief of Pediatric Gastroenterology, Hepatology, and Nutrition, Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, and Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai in New York. Dr. Dubinsky received her medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at CHI Sainte-Justine, University of Montreal, in Quebec, Canada. Board certified in pediatric gastroenterology, Dr. Dubinsky holds positions of prominence with several advisory bodies, including the presidency of We Care. She is a member of several professional societies, including the American Gastroenterology Association, the American College of Gastroenterology, and the American Academy of Pediatrics. Dr. Dubinsky’s work has been published in numerous peer-reviewed journals, including Gastroenterology, Nature Genetics, the Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology.
- Dr. Keefer is an academic health psychologist and the Director for Psychobehavioral Research within the Division of Gastroenterology. She specializes in the psychosocial care of patients with chronic digestive diseases, specifically inflammatory bowel diseases such as Crohn’s or ulcerative colitis. Dr. Keefer came to Mount Sinai in January 2016 from Chicago, IL to lead a subspecialty medical home for inflammatory bowel diseases (IBD). The Mount Sinai IBD medical home, known as GRITT-IBD(TM) focuses on gaining resilience through transitions as they occur across the lifespan of patients living with Crohn’s disease and ulcerative colitis. Dr. Keefer’s clinical and research interests are in IBD disease self-management, gut-directed hypnotherapy, resilience, the psychosocial care needs of emerging adults with chronic disease and cognitive-behavior therapy. She is a sought-after speaker and mentor. She chairs the Division of Psychogastroenterology within the Rome Foundation and is on the Council of the American Neurogastroenterology and Motility Society.